help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Endocrinology, doi:10.1210/en.2005-0451
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Take, I.
Right arrow Articles by Takahashi, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Take, I.
Right arrow Articles by Takahashi, N.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*PARATHYROID HORMONE
Endocrinology Vol. 146, No. 12 5204-5214
Copyright © 2005 by The Endocrine Society

Prostaglandin E2 Strongly Inhibits Human Osteoclast Formation

Ikuko Take, Yasuhiro Kobayashi, Yohei Yamamoto, Hideki Tsuboi, Takahiro Ochi, Setsuko Uematsu, Norimasa Okafuji, Saburo Kurihara, Nobuyuki Udagawa and Naoyuki Takahashi

Graduate School of Oral Medicine (I.T.), Institute for Oral Science (Y.K., N.T.), Department of Orthodontics (I.T., S.U., N.O., S.K.), and Department of Biochemistry (N.U.), Matsumoto Dental University, Nagano 399-0781, Japan; Department of Periodontology (Y.Y.), School of Dentistry, Aichi Gakuin University, Nagoya 464-8651, Japan; Department of Orthopedic Surgery, Osaka University Graduate School of Medicine (H.T.), Osaka 565-0871, Japan; and National Hospital Organization Sagamihara National Hospital (T.O.), Kanagawa 228-8522, Japan

Address all correspondence and requests for reprints to: Dr. Naoyuki Takahashi, Institute for Oral Science, Matsumoto Dental University, 1780 Hiro-oka Gobara, Shiojiri, Nagano 399-0781, Japan. E-mail: takahashinao{at}po.mdu.ac.jp.

Prostaglandin E2 (PGE2) enhances osteoclast formation in mouse macrophage cultures treated with receptor activator of nuclear factor-{kappa}B ligand (RANKL). The effects of PGE2 on human osteoclast formation were examined in cultures of CD14+ cells prepared from human peripheral blood mononuclear cells. CD14+ cells differentiated into osteoclasts in the presence of RANKL and macrophage colony-stimulating factor. CD14+ cells expressed EP2 and EP4, but not EP1 or EP3, whereas CD14+ cell-derived osteoclasts expressed none of the PGE2 receptors. PGE2 and PGE1 alcohol (an EP2/4 agonist) stimulated cAMP production in CD14+ cells. In contrast to mouse macrophage cultures, PGE2 and PGE1 alcohol inhibited RANKL-induced human osteoclast formation in CD14+ cell cultures. H-89 blocked the inhibitory effect of PGE2 on human osteoclast formation. These results suggest that the inhibitory effect of PGE2 on human osteoclast formation is mediated by EP2/EP4 signals. SaOS4/3 cells have been shown to support human osteoclast formation in cocultures with human peripheral blood mononuclear cells in response to PTH. PGE2 inhibited PTH-induced osteoclast formation in cocultures of SaOS4/3 cells and CD14+ cells. Conversely, NS398 (a cyclooxygenase 2 inhibitor) enhanced osteoclast formation induced by PTH in the cocultures. The conditioned medium of CD14+ cells pretreated with PGE2 inhibited RANKL-induced osteoclast formation not only in human CD14+ cell cultures, but also in mouse macrophage cultures. These results suggest that PGE2 inhibits human osteoclast formation through the production of an inhibitory factor(s) for osteoclastogenesis of osteoclast precursors.




This article has been cited by other articles:


Home page
BloodHome page
B. J. Frisch, R. L. Porter, B. J. Gigliotti, A. J. Olm-Shipman, J. M. Weber, R. J. O'Keefe, C. T. Jordan, and L. M. Calvi
In vivo prostaglandin E2 treatment alters the bone marrow microenvironment and preferentially expands short-term hematopoietic stem cells
Blood, November 5, 2009; 114(19): 4054 - 4063.
[Abstract] [Full Text] [PDF]


Home page
JDRHome page
M. Uchiyama, Y. Nakamichi, M. Nakamura, S. Kinugawa, H. Yamada, N. Udagawa, and H. Miyazawa
Dental Pulp and Periodontal Ligament Cells Support Osteoclastic Differentiation
Journal of Dental Research, July 1, 2009; 88(7): 609 - 614.
[Abstract] [Full Text] [PDF]


Home page
JDRHome page
Y. Yagi, N. Suda, Y. Yamakoshi, O. Baba, and K. Moriyama
In vivo Application of Amelogenin Suppresses Root Resorption
Journal of Dental Research, February 1, 2009; 88(2): 176 - 181.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
C.-H. Tang, R.-S. Yang, T.-H. Huang, D.-Y. Lu, W.-J. Chuang, T.-F. Huang, and W.-M. Fu
Ultrasound Stimulates Cyclooxygenase-2 Expression and Increases Bone Formation through Integrin, Focal Adhesion Kinase, Phosphatidylinositol 3-Kinase, and Akt Pathway in Osteoblasts
Mol. Pharmacol., June 1, 2006; 69(6): 2047 - 2057.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2005 by The Endocrine Society